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Solid organ transplant recipients, who are medically immunosuppressed to prevent graft rejection, have
increased melanoma risk, but risk factors and outcomes are incompletely documented. We evaluated melanoma
incidence among 139,991 non-Hispanic white transplants using linked US transplant-cancer registry data
(1987–2010). We used standardized incidence ratios (SIRs) to compare incidence with the general population and
incidence rate ratios (IRRs) from multivariable Poisson models to assess risk factors. Separately, we compared
post-melanoma survival among transplant recipients (n= 182) and non-recipients (n= 131,358) using multivariable
Cox models. Among transplant recipients, risk of invasive melanoma (n= 519) was elevated (SIR= 2.20, 95% CI
2.01–2.39), especially for regional stage tumors (SIR= 4.11, 95% CI 3.27–5.09). Risk of localized tumors was stable
over time after transplantation but higher with azathioprine maintenance therapy (IRR= 1.35, 95% CI 1.03–1.77).
Risk of regional/distant stage tumors peaked within 4 years following transplantation and increased with
polyclonal antibody induction therapy (IRR= 1.65, 95% CI 1.02–2.67). Melanoma-speciﬁc mortality was higher
among transplant recipients than non-recipients (hazard ratio 2.98, 95% CI 2.26–3.93). Melanoma exhibits
increased incidence and aggressive behavior under transplant-related immunosuppression. Some localized
melanomas may result from azathioprine, which acts synergistically with UV radiation, whereas T-cell–depleting
induction therapies may promote late-stage tumors. Our ﬁndings support sun safety practices and skin screening
for transplant recipients.
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INTRODUCTION
Melanoma is an aggressive form of skin cancer whose rapidly
increasing incidence represents a major public health
concern in the US (Siegel et al., 2014; United States
Department of Health and Human Services, 2014). Risk
factors include older age, family history, fair complexion,
exposure to UV radiation (UVR; Rhodes et al., 1987), and
higher counts of nevi (Olsen et al., 2010). Accordingly,
incidence is concentrated in non-Hispanic white persons
(Cormier et al., 2006) and among this group increases with
decreasing latitude of residence (Eide and Weinstock, 2005).
Melanoma risk has been reported to be increased two to
ﬁvefold among solid organ transplant recipients, who are
prescribed immunosuppressive medications to prevent graft
rejection (Jensen et al., 1999; Kasiske et al., 2004; Hollenbeak
et al., 2005; Grulich et al., 2007; Engels et al., 2011; Chatrath
et al., 2013; Dahlke et al., 2014). This elevation could result
from immune dysfunction or from direct carcinogenic effects
of some medications (Hojo et al., 1999; O'Donovan et al.,
2005; Han et al., 2012). In addition, transplant recipients are
screened intensively for skin cancer due to a very high risk of
cutaneous squamous-cell carcinoma (Ulrich et al., 2008).
Thus, the melanoma excess could partly represent
overdiagnosis, in which case it should be most pronounced
for early-stage tumors (Welch et al., 2005).
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Furthermore, immune response may be important in
controlling melanoma after diagnosis. This possibility is
supported by the recent success of immunomodulatory
therapies in treating patients with metastatic melanoma
(Hamid et al., 2013; Wolchok et al., 2013). If
immune response is important, one would predict that
melanomas would behave more aggressively when it is
impaired, and there is some evidence for increased melanoma
mortality among transplant recipients (Brewer et al., 2011;
Vajdic et al., 2014).
Clinical management of transplant recipients would be
informed by understanding of risk factors and outcomes for
melanoma in this population. Prior studies have been small,
and transplant-related risk factors are poorly documented.
In the present study, we evaluated the epidemiology of
melanoma in a large population of US transplant recipients
and assessed the impact of transplantation on melanoma
survival.
RESULTS
Incidence analysis
A total of 139,991 transplants in non-Hispanic white patients
contributed 701,358 person-years of follow-up for incident
melanoma (Table 1). Median follow-up time among all
transplants was 4.0 years (interquartile range 1.4–7.6 years);
this was similar across organ types with the exception of lung
recipients who had a median follow-up of 2.6 years. Most
transplants occurred in patients who were male (62.9%), aged
35–64 years (69.2%), and received a kidney (50.5%).
Transplants of the liver (24.6%), heart (11.7%), lung (5.9%),
and other or multiple organs (7.3%) were less common.
Invasive melanoma was diagnosed in 519 transplants and
in situ melanoma in 190 transplants (incidence rates
74.0 and 27.1 per 100,000 person-years, respectively). Risk
of invasive melanoma was elevated more than twofold
above the general population (standardized incidence ratio
(SIR) 2.20, 95% conﬁdence interval (CI) 2.01–2.39; Table 2).
Although risk was elevated across tumor stages, the
greatest increase was for regional stage melanoma
(SIR= 4.11, 95% CI 3.27–5.09). By tumor site, risk was
strongly elevated for melanomas on the head and neck
(SIR= 3.34, 95% CI 2.85–3.90), with more modest increases
for other sites. Risk was also elevated for in situ melanoma
(SIR= 1.47, 95% CI 1.27–1.69, Table 2).
Examination of melanoma risk by stage and time since
transplantation revealed two distinct patterns. Risk of regional
and distant stage melanoma increased markedly within 4 years
after transplantation (up to sixfold for regional stage tumors)
and then declined, whereas risk of in situ and localized
melanoma was elevated ~1.5- to 2-fold consistently over time
(Figure 1).
To investigate these patterns, we separately evaluated risk
factors for localized and regional/distant stage melanoma.
Supplementary Table 1 (online) shows adjusted associations
for UVR, medications, and transplant-related characteristics,
separately according to stage. We did not observe any
statistically signiﬁcant associations with our ecological
measures of UVR exposure, thus preventing their inclusion
in the ﬁnal models. However, we note that the trends for
localized stage tumors were suggestive (P-values for trend
across quintiles of 0.052 for average daily global solar
radiation (AVGLO) and 0.079 for latitude, Supplementary
Table 1 online). In our ﬁnal multivariable model for localized
melanoma (Table 3), higher risk was associated with male sex,
increasing age, and azathioprine maintenance therapy
(incidence rate ratio (IRR)= 1.35, 95% CI 1.03–1.77).
Compared with kidney recipients, risk was lower in liver
recipients (IRR= 0.60, 95% CI 0.45–0.80) and lung recipients
(IRR= 0.50, 95% CI 0.26–0.95). Incidence did not vary
signiﬁcantly by time since transplantation, although it was
suggestively higher in some later intervals.
In the multivariable model for regional/distant stage
melanoma (Table 3), risk increased with male sex, increasing
age, and polyclonal antibody induction therapy (IRR= 1.65,
95% CI 1.02–2.67). Incidence increased sharply in the ﬁrst 4
years after transplantation before steadily declining.
Survival analysis
For survival, we evaluated 131,540 patients diagnosed with
invasive melanoma, of whom 96% were of white race.
Melanomas were largely local stage (76%), with
smaller proportions of regional (8%), distant (4%), or
unknown stage (13%). On the basis of linkage to the Scientiﬁc
Registry of Transplant Recipients (SRTR), 182 melanomas
(0.14%) occurred in transplant recipients.
Over follow-up, 50 transplant recipients (27%) and 16,380
non-recipients (12%) died of melanoma. Additional deaths
were due to other causes (n= 42 recipients, n=19,527 non-
recipients).
Melanoma-speciﬁc mortality was elevated threefold in
transplant recipients compared with non-recipients (hazard
ratio (HR) 2.98, 95% CI 2.26–3.93, Table 4, Figure 2a).
This elevation in risk did not vary over time since melanoma
diagnosis (likelihood ratio P= 0.88) and did not change
after restricting to non-Hispanic whites (HR= 3.02, 95% CI
2.28–4.01).
After stratifying by melanoma stage, the association of
prior transplantation with melanoma-speciﬁc mortality was
strongest for localized stage melanomas (HR= 4.29,
95% CI 2.70–6.82), intermediate for regional stage
(HR= 3.83, 95% CI 2.34–6.28), and not elevated for distant
stage (HR= 1.30, 95% CI 0.54–3.13; Figure 2b, c, d). Among
localized melanomas, where known, surgical treatment was
reported for 96% of transplant recipients and 91% of
non-recipients. Restriction to localized melanoma cases
with reported surgery did not alter the association with
melanoma-speciﬁc mortality (HR= 4.55, 95% CI 2.82–7.33).
Among localized melanomas, mortality appeared increased
among transplant recipients for both thin tumors (o1mm,
HR= 4.74, 95% CI 2.12–10.6) and thick tumors (⩾1mm,
HR= 2.14, 95% CI 0.89–5.15).
DISCUSSION
In this large, representative series of solid organ transplant
recipients, invasive melanoma incidence was increased
over twofold above rates seen in the general population.
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We observed notable differences by tumor stage in the timing
of onset and melanoma risk factors. Also, melanoma-speciﬁc
mortality was elevated threefold compared with non-recipi-
ents, suggesting that melanoma behaves aggressively under
transplant-related immunosuppression.
One possible interpretation of our results for localized
melanoma is that medications that increase UVR-induced
DNA damage, coupled with continued UVR exposure,
contribute to the development of early melanomas. Incidence
of localized tumors was increased in recipients prescribed
azathioprine, which may accelerate UVR-induced DNA
damage (O'Donovan et al., 2005; Clarke et al., 2015). In
addition, we observed suggestive increases with two measures
of UVR exposure, AVGLO (Ptrend across quintiles=0.052) and
latitude (Ptrend across quintiles=0.079; Supplementary Table 1
online); we note that these measures are ecological and may
not be good proxies for individual-level exposure. Although
UVR exposure in early life may be most relevant for
melanoma (Holman et al., 1986; Nelemans et al., 1993),
the association with azathioprine suggests that UVR exposure
occurring after transplantation could also affect risk. One
caveat is that we only examined immunosuppressive
medications indicated at baseline. Also, although we
adjusted for calendar year of transplantation, there have
been strong time trends in medication use, which may have
led to residual confounding and impacted these results.
Compared with kidney recipients, we observed lower risk for
localized melanoma among liver and lung recipients, but we
do not have an explanation for this particular result.
For regional and distant stage melanoma, we found a high
risk soon after transplantation that may relate to short-term,
intense immunosuppression. Risk of regional/distant stage
tumors peaked within 4 years of transplantation and increased
with T-cell–depleting polyclonal antibody induction therapy.
Each of these patterns was also observed for melanoma
overall in an Australian study (Vajdic et al., 2009). Consistent
with a short-term effect of intense immunosuppression,
melanoma incidence declines after graft failure in kidney
recipients, when patients return to dialysis and immunosup-
pressive therapy is ceased or reduced (Vajdic et al., 2009;
van Leeuwen et al., 2010).
Although the steady incidence of localized melanomas
after transplantation may represent the occurrence of de novo
tumors, a plausible explanation for the sharp increase in
regional and distant melanoma is that melanocytic precursors
or early-stage melanomas were already present but undiag-
nosed at the time of transplant, and they progressed rapidly
with intense immune suppression. Consistent with this model,
melanocytic nevus counts increase after transplantation
(Smith et al., 1993; Grob et al., 1996), sometimes in an
eruptive manner and/or with the presence of dysplasia (Barker
and MacDonald, 1988; McGregor et al., 1991). Melanomas
express a range of neoantigens that can serve as targets for
T cells (Lennerz et al., 2005), and among melanoma patients
lower host immune response to the tumor (as measured by
tumor-inﬁltrating lymphocytes) is associated with a larger
tumor size and a greater likelihood of sentinel lymph node
positivity (Taylor et al., 2007; Azimi et al., 2012). The excess
risk of regional and distant stage melanoma observed here is
inconsistent with overdiagnosis, as frequent skin cancer
screening in transplant recipients would shift the stage
distribution downward (Welch et al., 2005). In passing, we
note that melanoma can be transmitted from donors to
recipients through the donated organ, but such a transmission
is very rare and does not likely account for our ﬁndings
(MacKie et al., 2003; Strauss and Thomas, 2010).
Our survival analysis supports a further role for immune
response in controlling melanoma progression after clinical
diagnosis. Transplant recipients had a threefold increased risk
of dying from their melanoma compared with melanoma
patients without a transplant; this is generally consistent with
most (Brewer et al., 2011; Vajdic et al., 2014), but not all
(Matin et al., 2008), prior studies. The strong association for
Table 1. Demographic characteristics of 139,991 non-
Hispanic white organ transplant recipients, US
Transplant Cancer Match Study
Characteristic n Percentage
Sex
Male 88,051 62.9
Female 51,940 37.1
Age at transplantation (years)
0–19 10,619 7.6
20–34 18,519 13.2
35–49 42,267 30.2
50–64 54,598 39.0
65+ 13,988 10.0
Transplanted organ
Kidney 70,729 50.5
Liver 34,487 24.6
Heart 16,325 11.7
Lung 8,243 5.9
Other or multiple 10,207 7.3
Year of transplantation
1987–1998 53,105 37.9
1999–2002 30,009 21.4
2003–2005 24,185 17.3
2006–2010 32,692 23.4
The cohort includes transplant recipients in California (years of follow-up:
1988–2008, n=22,792 transplants), Colorado (1988–2009, n= 4,233),
Connecticut (1987–2009, n= 3,254), Florida (1987–2009, n=15,703),
Georgia (1995–2010, n=6,372), Hawaii (1987–2007, n=298),
Illinois (1987–2007, n=12,146), Iowa (1987–2009, n=4,542), Michigan
(1987–2009, n= 11,720), New Jersey (1987–2010, n= 9,550), New York
(1987–2010, n=18,500), North Carolina (1990–2010, n=7,859),
Seattle (1987–2008, n= 4,209), Texas (1995–2010, n= 15,915), and Utah
(1987–2008, n=2,898).
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localized tumors—including for thin tumors with Breslow
thickness o1mm—implies that there may be subclinical
spread of these tumors in transplant recipients and, in turn,
that intact immune responses may normally prevent this
spread. Importantly, although our data on surgical treatment
were limited, our sensitivity analysis did not support that
treatment differences explain the decreased survival of
transplant recipients. In other contexts, survival following a
melanoma diagnosis correlates with multiple measures of the
cellular immune response including density, distribution, and
activation of tumor-inﬁltrating lymphocytes (van Houdt et al,
2008; Azimi et al, 2012).
Melanoma risk is increased among immunocompromised
populations other than transplant recipients (Kubica and
Brewer, 2012). People infected with HIV experience an
excess (Grulich et al, 2007), but it is smaller, possibly due
to differences in the mechanism or rapidity of onset of
immunosuppression or to differences in population structure,
which can confound SIR comparisons. Chronic lymphocytic
leukemia (CLL) is a malignancy characterized by immuno-
suppression, which can be intensiﬁed by CLL treatment, and
melanoma risk is approximately threefold increased among
CLL patients (Travis et al, 1992; Adami et al, 1995; Hisada
et al, 2001). Survival after melanoma may also be decreased
in these populations (Rodrigues et al, 2002; Brewer
et al, 2012).
Our complementary analyses of melanoma incidence and
survival allowed us to assess the impact of immunosuppres-
sion along a continuum of outcomes. Linkage of transplant
and cancer registries yielded a population-based sample of
nearly half of the US transplant population, and cancer
registries provided systematic ascertainment of melanomas, as
well as information on stage, site, and melanoma-speciﬁc
mortality. Our study is also subject to the typical limitations of
analyses based on registry data. We were limited in our ability
to assess some clinically relevant information (e.g., tumor
Clark’s level and Breslow thickness, sentinel lymph node
biopsy, details on surgeries) because data were incomplete or
unavailable. Our survival analyses were based on death
certiﬁcate-coded cause of death, which could be inaccurate
for transplant recipients who have multiple chronic medical
issues. There is also the possibility of differential diagnosis,
staging, or reporting of melanoma for transplant recipients
compared with non-recipients. For example, transplant
recipients may be more likely to be diagnosed with advanced
melanomas in hospital settings, where reporting to cancer
registries is more complete than for thinner tumors diagnosed
in dermatology ofﬁces (Cockburn et al., 2008), and because
of their poorer health they may receive a different diagnostic
work-up compared with non-recipients. On the other hand,
the identiﬁcation of melanoma may be more difﬁcult among
transplant recipients if the frequent presence of other skin
lesions makes some melanomas difﬁcult to identify. Finally,
although the associations that we observed with melanoma
incidence (e.g., for azathioprine maintenance and polyclonal
antibody induction) could indicate causal effects, we cannot
rule out that they are due to bias, chance, unmeasured
confounding factors, or other complexities related to the
analysis of linked data sets.
Because risk for multiple types of skin cancer is high,
transplant recipients should be encouraged to minimize
unnecessary UVR exposure and adopt sun-protective behav-
iors (Ulrich et al., 2009). Our results also highlight the
importance of a thorough dermatologic evaluation for
transplant candidates before transplantation, with the goal of
detecting and removing both small melanomas and precursor
lesions that could rapidly progress to invasive melanoma.
Close monitoring within 4 years of transplantation is
warranted, particularly for recipients with risk factors for
late-stage melanoma such as male sex, older age, or receipt of
T-cell–depleting induction therapy. For transplant recipients
Table 2. Melanoma risk among 139,991 non-Hispanic
white transplant recipients compared with the general
population
Melanoma characteristic Melanoma cases (n) SIR (95% CI)
All invasive melanomas 519 2.20 (2.01, 2.39)
By tumor stage
Localized 365 2.03 (1.83, 2.25)
Regional 83 4.11 (3.27, 5.09)
Distant 22 2.16 (1.36, 3.27)
Unknown 49 1.88 (1.39, 2.49)
By tumor site
Head and neck 161 3.34 (2.85, 3.90)
Trunk 162 1.92 (1.63, 2.24)
Lower limbs 117 2.05 (1.70, 2.46)
Upper limbs 49 1.44 (1.07, 1.90)
Other/NOS 30 2.37 (1.60, 3.39)
In situ melanomas 190 1.47 (1.27, 1.69)
Abbreviations: CI, conﬁdence interval; NOS, not otherwise speciﬁed;
SIR, standardized incidence ratio.
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Figure 1. Standardized incidence ratios comparing melanoma incidence in
139,991 non-Hispanic white transplant recipients with the general
population, stratiﬁed by time since transplantation and melanoma stage.
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who do develop melanoma, physicians should perform an
appropriate staging evaluation, including a clinical
assessment of lymph node involvement and other distant
spread (Fong and Tanabe, 2014). Along with surgery directed
at the primary tumor, treatment should incorporate reduction
or revision of immunosuppression, to the extent possible, to
facilitate immunologic control of the tumor.
In conclusion, transplant recipients have an elevated risk of
melanoma that may be related to immunosuppressive
medications used for transplant induction and maintenance.
Table 3. Multivariable models for melanoma incidence among 139,991 non-Hispanic white transplant recipients,
stratiﬁed by melanoma stage
Characteristic
Localized stage Regional and distant stage
na IRR (95% CI) Phet n
a IRR (95% CI) Phet
Attained age, per categoryb 365 1.85 (1.64, 2.10) 105 1.78 (1.42, 2.24)
Sex
Female 92 Reference 23 Reference
Male 273 1.64 (1.29, 2.09) 82 1.89 (1.18, 3.02)
Transplanted organ 0.002 0.075
Kidney 203 Reference 54 Reference
Liver 63 0.60 (0.45, 0.80) 24 0.97 (0.59, 1.60)
Heart 72 0.91 (0.69, 1.21) 24 1.35 (0.82, 2.22)
Lung 10 0.50 (0.26, 0.95) 1 0.22 (0.03, 1.61)
Other or multiple 17 0.89 (0.54, 1.46) 2 0.37 (0.09, 1.52)
Time since transplantation, years 0.120 0.066
0–0.5 21 Reference 5 Reference
0.6–1.5 54 1.42 (0.86, 2.35) 19 2.13 (0.79, 5.71)
1.6–4.0 98 1.26 (0.79, 2.03) 43 2.45 (0.97, 6.23)
4.1–8.0 124 1.63 (1.01, 2.63) 25 1.44 (0.54, 3.86)
8.1–12.0 52 1.46 (0.86, 2.49) 10 1.23 (0.41, 3.75)
412.0 16 0.96 (0.49, 1.89) 3 0.86 (0.20, 3.77)
Year of transplantation 0.306 0.299
1987–1998 189 Reference 46 Reference
1999–2002 83 1.02 (0.76, 1.38) 31 1.27 (0.79, 2.03)
2003–2005 60 1.33 (0.95, 1.88) 13 0.79 (0.41, 1.50)
2006–2010 33 1.29 (0.84, 1.99) 15 1.46 (0.77, 2.78)
Azathioprine maintenance therapy
No 235 Reference
Yes 130 1.35 (1.03, 1.77)
Polyclonal antibody induction therapy
No 81 Reference
Yes 24 1.65 (1.02, 2.67)
Abbreviations: CI, conﬁdence interval; IRR, incidence rate ratio (mutually adjusted); Phet, P-value for heterogeneity (likelihood ratio test, provided for variables
with more than two levels).
aNumber of melanoma cases of the speciﬁed tumor stage that occurred in this category.
bAttained age (i.e., current age) was modeled in ﬁve categories (0–19, 20–34, 35–49, 50–64, and ⩾65 years) with one degree of freedom.
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Compared with melanomas in immunocompetent people,
melanomas in transplant recipients occur at advanced stage
and are associated with poor survival. Evaluation of risk in
other immunocompromised populations, as well as molecular
characterization of tumors in immunosuppressed patients,
may yield further clues to the relationship between immune
responses and melanoma.
MATERIALS AND METHODS
Incidence analysis
The Transplant Cancer Match Study (www.transplantmatch.cancer.
gov) links the SRTR, which captures data on all transplants occurring
in the US, with 15 population-based cancer registries (Engels et al,
2011). Linkage between the SRTR and cancer registries was
performed using a probabilistic matching algorithm based on
name, sex, date of birth, and social security number, followed by
clerical review of potential matches. The resulting cohort includes
46.5% of the US transplant population during 1987–2010––
speciﬁcally, transplant recipients in California (years of follow-up:
1988–2008), Colorado (1988–2009), Connecticut (1987–2009),
Florida (1987–2009), Georgia (1995–2010), Hawaii (1987–2007),
Illinois (1987–2007), Iowa (1987–2009), Michigan (1987–2009),
New Jersey (1987–2010), New York (1987–2010), North Carolina
(1990–2010), Seattle (1987–2008), Texas (1995–2010), and Utah
(1987–2008; see Table 1 footnote for numbers of transplants by
registry). The Transplant Cancer Match Study was approved by
human subjects research review committees at the National Cancer
Institute and, as required, at participating cancer registries.
The outcome for our incidence analysis was ﬁrst diagnosis of
cutaneous melanoma (invasive or in situ); subsequent melanoma
diagnoses were not further considered. Transplant recipients were
followed from the later of transplantation or beginning of cancer
registry coverage and exited at the earliest of melanoma diagnosis,
organ failure, a subsequent transplant, loss to follow-up, death, or
end of cancer registry coverage. Transplants performed at different
times on the same individual were considered separately. We
restricted analysis to non-Hispanic whites, as only 26 invasive
melanoma cases occurred outside of this group. We further excluded
320 transplants with melanoma diagnosed before transplantation and
128 transplants in people with HIV infection.
We compared melanoma risk in transplant recipients with the
general population using SIRs. SIRs were calculated as the number of
observed melanoma cases divided by the number expected, based
on general population rates speciﬁc to registry, 5-year age group, sex,
race/ethnicity, and calendar year. We estimated SIRs overall, by
tumor stage and site, and in cross-classiﬁed categories by tumor stage
and time since transplantation. For tumor stage, we used the
summary-stage variable, which has three levels (local, regional,
and distant) and is largely complete in cancer registries. Summary
stage allows summarization of different and regularly updated
clinical staging systems (e.g., American Joint Committee on Cancer
editions), thus enabling reliable classiﬁcation of stage for patients
diagnosed over time.
We used zip codes of residence provided by the SRTR to link
transplants to two ecological measures of UVR exposure, which we
divided into quintiles of equal range (after excluding extreme outliers).
The ﬁrst was latitude, which we assigned using a public database
(CivicSpace Labs, 2004). The second was a measure of predicted
30-year AVGLO that has been associated with melanoma risk
(Tatalovich et al., 2006a,b). Some recipients could not be assigned
these measures based on their zip code. For recipients in states where
the range of latitude or county-level AVGLO ﬁt completely or very
nearly within a pre-deﬁned quintile, we imputed quintiles with a
maximum error of 0.5 degrees (latitude) or 41 watt-hours per square
kilometer (AVGLO). For latitude, we combined the lower two quintiles
(high/highest UVR) owing to sparse observation time.
Table 4. Comparison of melanoma-speciﬁc survival after melanoma diagnosis among 131,540 US transplant
recipients and non-recipients
Melanoma characteristic
Melanoma cases, n Melanoma deaths, n (% of cases) Adjusted HR for melanoma-speciﬁc
mortality (95% CI)
Transplant recipients Non-recipients Transplant recipients Non-recipients
All invasive melanomas 182 131,358 50 (27) 16,380 (12) 2.98 (2.26, 3.93)
By tumor stage
Localized 121 99,260 18 (15) 6,229 (6) 4.29 (2.70, 6.82)
Regional 26 9,918 16 (62) 3,106 (31) 3.83 (2.34, 6.28)
Distant 8 5,734 5 (63) 3,731 (65) 1.30 (0.54, 3.13)
Unknown 27 16,446 11 (41) 3,314 (20) 1.87 (1.03, 3.38)
By thickness, among localized melanomas
Thin (o1mm) 59 52,368 6 (10) 1,674 (3) 4.74 (2.12, 10.6)
Thick (⩾1mm) 28 16,333 5 (18) 2,205 (14) 2.14 (0.89, 5.15)
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
The cohort includes melanoma cases in transplant recipients and non-recipients followed for death due to melanoma in Colorado (years of melanoma
diagnosis and follow-up: 1988–2009; number melanoma cases=14,367), Connecticut (1987–2009, n=15,103), Georgia (1995–2010, n= 22,331),
Iowa (1987–2009, n=11,189), New Jersey (1987–2010, n=31,883), and Texas (1995–2010, n=36,667). HRs are adjusted for age (in categories of
0–20, 21–30, 31–40, 41–50, 51–60, 61–70, 71–80, 81–90, and 490 years), sex, race (white, non-white), year of melanoma diagnosis (1987–1994,
1995–1999, 2000–2005, and 2006–2010), and primary site (head and neck, upper limb and shoulder, trunk, lower limb and hip, and overlapping/not
otherwise speciﬁed). The overall HR for all invasive melanomas is additionally adjusted for tumor stage (localized, regional, distant, and unknown).
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We calculated IRRs to compare incidence between groups of
transplant recipients. We adjusted, a priori, for age, sex, transplanted
organ, time since transplantation, and year of transplantation
(see Table 3 for details). We estimated adjusted IRRs for groups
deﬁned by receipt of individual induction and maintenance
medications (as recorded at the time of transplant), UVR exposure
(latitude and AVGLO) and for kidney recipients, by living/deceased
donor status and history of acute rejection. On the basis of these
results, we included variables with signiﬁcant IRRs (Po0.05) in
multivariable Poisson models. As described in the Results section,
these models were ﬁt separately for localized and regional/distant
stage melanoma, because we observed different patterns of
incidence over time by tumor stage suggestive of distinct biological
processes.
Survival analysis
To compare survival after melanoma diagnosis between transplant
recipients and non-recipients, we used data from a subset of the
cancer registries in the Transplant Cancer Match Study. Of the eight
registries providing vital status follow-up and cause of death
information, we eliminated two that appeared to have incomplete
follow-up for mortality. Our study population for survival analysis
thus included data from Colorado (years of melanoma diagnosis and
follow-up: 1988–2009), Connecticut (1987–2009), Georgia
(1995–2010), Iowa (1987–2009), New Jersey (1987–2010), and
Texas (1995–2010; see Table 4 footnote for numbers of melanoma
cases by registry). Among individuals in the general population who
were diagnosed with melanoma (i.e., both transplant recipients and
non-recipients), we restricted to melanoma cases occurring as an
individual’s ﬁrst diagnosis of invasive cutaneous melanoma
(n= 134,096). We then excluded cases with missing/unknown cause
of death (n= 2,556). The survival analysis included patients of all
races/ethnicities.
Melanoma patients were classiﬁed as transplant recipients if they
linked to a transplant in the SRTR that occurred before their
melanoma diagnosis. Other individuals were classiﬁed as non-
recipients. Individuals who received transplants after melanoma
diagnosis (n= 72) were classiﬁed as non-recipients and were
censored at transplantation.
The primary survival outcome was death due to melanoma, which
we assessed using underlying cause of death codes indicated on
death certiﬁcates. Follow-up time began at melanoma diagnosis and
ended at the ﬁrst of death, loss to follow-up, or the end of cancer
registry ascertainment of deaths. Individuals were censored if they
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Figure 2. Melanoma-speciﬁc mortality after invasive melanoma for transplant recipients compared with non-recipients. Comparisons are shown overall (a) and
by stage of melanoma: localized (b), regional (c), and distant (d).
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died of another cause or were still living at the end of cancer registry
coverage. We calculated melanoma-speciﬁc survival estimates using
the Kaplan–Meier method.
We ﬁt a Cox proportional hazards model to assess the effect of
transplant status, adjusting for age, sex, race, diagnosis year, tumor
site, and tumor stage (see Table 4 footnote for details). We tested
the proportional hazards assumption for transplant status by
allowing different HRs for four intervals after melanoma diagnosis
(o1, 1–1.9, 2–2.9, and ⩾ 3 years). Separately, we ﬁt models stratiﬁed
by tumor stage.
We performed three sensitivity analyses. First, we restricted to non-
Hispanic whites diagnosed beginning in 1992 (when Hispanic
ethnicity data became available). Second, we aimed to assess
whether possible treatment differences between transplant recipients
and non-recipients inﬂuenced survival differences. Localized mela-
nomas comprised the majority of cases, and transplantation was most
strongly associated with mortality in this group. Therefore, in the
second sensitivity analysis, we restricted to localized cases who were
reported by cancer registries to have received surgical treatment.
Finally, Breslow thickness was unknown or missing for 42% of
melanoma cases, precluding its inclusion in the primary analysis. As
a sensitivity analysis, where Breslow thickness was known, we
classiﬁed localized melanomas as thin (o1mm) or thick (⩾1mm)
and evaluated the effect of transplantation in each category.
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